ALYSSA INGLE: Open Payments
NPI 1841927449 · BREMEN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$284 in 15 payments from 9 companies in 2025. Trend: 2023 $249 · 2024 $220 · 2025 $284
Food & beverage: $284
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| ABBVIE INC. | 3 | $48 |
| Abbott Laboratories | 2 | $36 |
| Novo Nordisk Inc | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $17 |
Products named: VRAYLAR, BREZTRI, FREESTYLE LIBRE 3, Auvelity, AIRSUPRA, Rybelsus, JARDIANCE, Kerendia.
Industry payments across IN — which companies pay providers there.
